Oncology

Updates on the evolving treatment landscape in HER2+ eBC presented at ASCO 2026, highlighting the role of trastuzumab deruxtecan…

PATHFINDER 2 and NHS-Galleri population-scale studies show that a multi-cancer early detection (MCED) blood test increased screen-detected…

Data from the innovative, patient-centered, Phase II ARACOG study presented at ASCO 2026, evaluating cognitive outcomes with darolutamide…

Data presented at ASCO 2026, ESMO 2025/26, and SABCS 2025 from DESTINY-Breast03 and DESTINY-Breast09 evaluated T-DXd…

Updated data from the Phase I DAREON-8 trial of the novel DLL3 targeting T-cell engager, obrixtamig, presented at ASCO 2026, showing…

ASCO 2026 highlights in HR+ metastatic breast cancer include new insights into endocrine resistance, ctDNA-guided monitoring…

Moving back and forth among the bedside, the laboratory, and the policy arena has given me a wide view of health. As a medical oncologist…

Understand how poor-prognosis features may impact clinical decision-making in patients with unresectable hepatocellular carcinoma…